【まだ間に合う】この四毒を意識しないとマンジャロを使っても一向に痩せません。

👉️Manjaro's online consultations are available via [Official LINE] https://lstep.app/zXFPzsp ◆━━━━━━━━━━━━━━━━━━◆ \ Achieve your last diet ever! 🔥 / ✅ Say goodbye to strict exercise and diet restrictions! ✅ Over 10,000 successful cases! Knowledge and clinical experience based on medical evidence ✅ Thorough follow-up after prescription \ For consultations and online consultations, please use our official LINE 💁‍♂️ / Dr. Kenshin will respond directly! https://lstep.app/zXFPzsp ▼Video Table of Contents▼ 00:00 Opening 01:04 Why Manjaro may not be effective 01:18 The relationship between insulin toxicity and blood sugar spikes 03:18 Visceral fat toxicity and the risk of chronic inflammation 04:24 The impact of fatty liver toxicity on metabolism 05:29 Energy stagnation toxicity and the mechanism of stagnation 06:35 The vicious cycle of four interconnected toxins 07:42 Why metformin is attracting attention 09:31 How to take metformin and precautions 10:36 Summary & Official LINE Information ● Official LINE https://lstep.app/zXFPzsp ● Instagram   / tsukuba_ken_clinic   ● TikTok   / diet_dr.kenshin   ● Homepage https://tsukuken.clinic ● For Media Inquiries/Business Requests: [email protected] ────────────────── 【About Treatment】(Disclosure of Important Information) 1. About Medical Treatment and Prescriptions at Our Clinic At our clinic, we may prescribe type 2 diabetes medications (GLP-1 receptor agonists, SGLT2 inhibitors, metformin, etc.) as private medical treatment (for obesity treatment purposes) at the doctor's discretion. Since these medications are not approved for use in Japan for obesity treatment, this constitutes off-label use. We will make a comprehensive judgment based on examination, test results, and medical history, and we cannot prescribe these medications to all patients. 2. Primary Purpose and Indications of Treatment All medications are approved for the purpose of controlling blood glucose in type 2 diabetes. Use for obesity treatment will be carried out only after thorough explanation and informed consent, taking into account domestic and international approval status and academic society guidelines. 3. Individual Differences in Efficacy, Side Effects, and Risks Taking the medication or injecting it does not necessarily guarantee a certain level of weight loss. There are significant individual differences in effectiveness, and it is essential to use it in conjunction with lifestyle changes, dietary therapy, and exercise therapy. Side effects such as hypoglycemia and gastrointestinal symptoms may occur; consult a doctor immediately if you experience any discomfort. 4. Possibility of Tests and Additional Treatment Regular tests (blood, urine, etc.) may be necessary to continue treatment. Consultation fees, test fees, and additional medication costs may be incurred separately. 5. Precautions Regarding Private Medical Treatment Prescriptions for obesity treatment are not covered by health insurance (full self-payment). Because it is an off-label use, it may not be covered by the national drug side effect relief system. 6. Comparison with Other Treatments and Guarantees This treatment is merely one option and does not guarantee superiority over other medical institutions or other treatments. Treatment effectiveness and the risk of side effects vary from person to person, and the expected results are not always guaranteed. ────────────────── ●GLP-1 Receptor Agonist (Oral Medication: Rybelsus) 【Treatment Details】 Rybelsus is an oral GLP-1 receptor agonist used to control blood glucose in type 2 diabetes. At our hospital, it may be prescribed for obesity treatment at the doctor's discretion (off-label use). Weight loss is expected due to its appetite-suppressing effect and sustained satiety. 【Dosage and Administration】 Take once daily before breakfast with 120 mL or less of water. Avoid eating or drinking for 30 minutes after taking the medication (to maximize its effect). The initial dose is 3 mg, increased to 7 mg after one month, and can be increased up to 14 mg as needed. [Standard Costs] Rybelsus 3mg 30-day supply: ¥8,480 7mg 30-day supply: ¥18,480 14mg 30-day supply: ¥26,980 [Main Risks and Side Effects] Gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), loss of appetite, acute pancreatitis (extremely rare) [Regarding the Use of Unapproved Drugs, etc.] Rybelsus is approved by the Ministry of Health, Labour and Welfare as a treatment for type 2 diabetes, but its prescription for the treatment of obesity is not approved in Japan. [Regarding the Source of Acquisition] This drug is procured from a domestic authorized distributor (pharmaceutical wholesaler). [Availability of Domestically Approved Drugs] Ugobi, which contains the same active ingredient as Rybelsus, and Sanorex, etc., are approved in Japan as treatments for obesity. [Information Regarding Safety in Other Countries] An injectable formulation conta...